Journal of Leukemia

Journal of Leukemia
Open Access

ISSN: 2329-6917

+44 1300 500008

Journal of Leukemia : Citations & Metrics Report

Articles published in Journal of Leukemia have been cited by esteemed scholars and scientists all around the world. Journal of Leukemia has got h-index 11, which means every article in Journal of Leukemia has got 11 average citations.

Following are the list of articles that have cited the articles published in Journal of Leukemia.

  2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Total published articles

50 56 62 62 23 11 8 22 23 48 50 29

Research, Review articles and Editorials

38 44 28 40 2 7 7 14 10 24 27 18

Research communications, Review communications, Editorial communications, Case reports and Commentary

12 12 34 22 21 4 1 8 13 24 23 11

Conference proceedings

0 0 0 0 0 0 0 28 0 0 0 0

Citations received as per Google Scholar, other indexing platforms and portals

0 0 0 54 59 64 98 0 74 0 0 0
Journal total citations count 618
Journal impact factor 2.11
Journal 5 years impact factor 3.71
Journal cite score 3.91
Journal h-index 11
Journal h-index since 2019 8
Important citations (462)

dhama n, babu a, sharma n. research & reviews: journal of medical and health sciences.

Gv rr. types of cancer and surgery in rats (rattus norvegicus). growth.;91:95.

Shukla p. umbilical cord preservation-a review. biochem mol biol lett. 2017;3(1):109.

Vosoughi t, bagheri m, hosseinzadeh m, ehsanpour a, davari n, saki n. cd markers variations in chronic lymphocytic leukemia: new insights into prognosis. journal of cellular physiology. 2019 may 2.

黄霞, 崔晶娴, 陈烨, 葛仁美. 胃癌组织中 ceacam6 的检测及其与 t 细胞的相互作用. 临床与病理杂志. 2018 nov 27;38(11):2395-401.

bae j, samur m, richardson p, munshi nc, anderson kc. selective targeting of multiple myeloma by b cell maturation antigen (bcma)-specific central memory cd8+ cytotoxic t lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. leukemia. 2019 mar 12:1.

gv rr. types of cancer and surgery in rats (rattus norvegicus). growth.;91:95.

shi w, chen z, li l, liu h, zhang r, cheng q, xu d, wu l. unravel the molecular mechanism of xbp1 in regulating the biology of cancer cells. journal of cancer. 2019;10(9):2035.

slean gr, silkiss rz. lenalidomide-associated thyroid-related eyelid retraction. ophthalmic plastic & reconstructive surgery. 2018 mar 1;34(2):e46-8.

cherian ma, olson s, sundaramoorthi h, cates k, cheng x, harding j, martens a, challen ga, tyagi m, ratner l, rauch d. an activating mutation of interferon regulatory factor 4 (irf4) in adult t-cell leukemia. journal of biological chemistry. 2018 may 4;293(18):6844-58.

bae j, hideshima t, zhang gl, zhou j, keskin db, munshi nc, anderson kc. identification and characterization of hla-a24-specific xbp1, cd138 (syndecan-1) and cs1 (slamf7) peptides inducing antigens-specific memory cytotoxic t lymphocytes targeting multiple myeloma. leukemia. 2018 mar;32(3):752.

bae j, hideshima t, tai yt, song y, richardson p, raje n, munshi nc, anderson kc. histone deacetylase (hdac) inhibitor acy241 enhances anti-tumor activities of antigen-specific central memory cytotoxic t lymphocytes against multiple myeloma and solid tumors. leukemia. 2018 sep;32(9):1932.

shukla p. umbilical cord preservation-a review. biochem mol biol lett. 2017;3(1):109.

minarik j, novak m, flodr p, balcarkova j, mlynarcikova m, krhovska p, pika t, pikalova z, bacovsky j, scudla v. cd 38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy. european journal of haematology. 2017 aug;99(2):186-9.

Hematuria as the first sign of multiple myeloma

A thrombo-hemorrhagic picture related to a hypoprothrombinemia syndrome - lupus anticoagulant revealing a multiple light chain myelomathrombo-haemorrhagic disease-related hypoprothrombinemia-lupus anticoagulant syndrome revealing a light chains multiple myeloma

Chronic lymphocytic leukemia and cardiotoxicity: problems and prospects

A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia

stadler n, shang a, bosch f, briggs a, goede v, berthier a. lshtm research online. adv ther. 2016;33:1814-30.

kamini j. why imatinib is by far the best drug to treat chronic myeloid leukemia. biochem mol biol lett. 2017;3(2):112.

Top